22 October 2021 NICE Multiple Technology Appraisal (MTA) Healthcare Improvement Scotland advises on adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed.
11 October 2021 October 2021 decisions news release SMC accepts three new medicines for use by NHSScotland The Scottish Medicines Consortium (SMC) which advises on newly licensed medicines for use by NHSScotland has today (Monday 11 October) published advice accepting three new medicines.
13 September 2021 September 2021 decisions news release SMC accepts three new medicines for use by NHS Scotland The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 13 September 2021) published advice accepting three new medicines.
1 September 2021 Extension of the interim acceptance decision option From September 2021 the interim acceptance decision option has been extended to include medicines with MHRA Early Access to Medicines Scheme (EAMS) and/or Innovative Licensing and Access Pathway (ILAP) status.
9 August 2021 August 2021 decisions news release SMC accepts six new medicines for use by NHS Scotland The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 9 August) published advice accepting six new medicines.
3 August 2021 MHRA: the regulator for new medicines in Scotland As the Medicines and Healthcare products Regulatory Agency (MHRA) is now the sole regulator of new medicines for use in NHSScotland, we are in the process of updating external facing and internal documents that make reference to the European Medicines Agency (EMA) regulatory process.
12 July 2021 July 2021 decisions news release SMC accepts three new medicines for use by NHSScotland The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 12 July) published advice accepting three new medicines.
11 June 2021 Ultra Orphan Validation Process SMC Executive has recently agreed an update to the ultra-orphan validation process such that from 1st September, ultra-orphan validation decisions will expire after 2 years. Thereafter if a product has MHRA marketing authorisation; if there are eligible patients in NHSScotland; and if no submission
7 June 2021 June 2021 decisions news release Five new medicines accepted for use by SMC Advice on five new medicines for use in conditions including advanced gastric cancer and chronic lymphocytic leukaemia has today (Monday 7 June) been published by the Scottish Medicines Consortium.
10 May 2021 May 2021 decisions news release Medicines for colorectal cancer, skin cancer and ovarian cancer among four accepted for use by NHSScotland The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has announced today (Monday 10 May) that it has accepted four new medicines for routine use.
